PET/CT

Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.

Telix says new kidney cancer imaging agent alters treatment plans for 50% of patients
The positive findings come after the U.S. Food and Drug Administration previously shared concerns related to sterility assurance issues during the drug’s production.
UCLA launches ‘first of its kind’ new standalone Department of Nuclear Medicine and Theranostics
“Becoming an independent department elevates this work and strengthens UCLA’s role in shaping the future of precision health," said the department's new acting chairman.
Largest network of private cardiology groups in US to deploy GE HealthCare's cardiac PET tracer
One of the tracer’s more significant advantages is its extended half-life of 109 minutes—significantly longer than other currently available PET MPI imaging agents.
Some PET exams may be overutilized in oncology
In 2020 alone, there were more than 2 million 18F-FDG PET/CT scans conducted in the United States.
PSMA-PET imaging not the most cost-effective option for many prostate cancer patients
The exam effectively helps providers manage patients’ treatment options, but for some, the costs associated with those treatments may negate the value of its findings.

New lesion measurement assesses treatment responses more accurately than RECIST

Researchers believe the new method of assessing treatment responses could pave the way for developing new cancer therapeutics.

A new Alzheimer's drug therapy appears effective. What might this mean for the future of amyloid PET?

Previously, CMS determined that coverage for patients receiving treatment was dependent on their being enrolled in a CMS-approved clinical trial under coverage with evidence development (CED).

FDG-PET shown to predict pancreatic cancer outcomes prior to surgery, could guide treatment decisions

FDG-PET scans in these patients allow clinicians to determine whether the tumors are still viable or not, thus playing a significant role in making treatment decisions.

PET imaging uncovers a surprising new way COVID-19 affects the heart

A new study in JACC: Cardiovascular Imaging focuses on a potential new side effect of COVID-19, highlighting the continued importance of monitoring these patients going forward.

5 ways to recruit sorely needed patients for Alzheimer’s clinical trials involving therapeutics

The demand is especially great for asymptomatic individuals of all races and ethnicities.

Whole-body PET image reveals body's immune response to COVID

In the study, patients who had recovered from an COVID infection were injected with a small amount of the 89Zr-labeled radiotracer before undergoing a uExplorer PET/CT scan.

18F-FDG PET/CT radiomics nomogram provides detailed insight into neuroblastoma

Better risk stratification can improve clinical decision making and better outcomes, experts involved in the study explained in EJR.

New PET imager cleared for U.S. sales

A Canadian manufacturer of positron emission tomography equipment has received FDA’s OK to market a small-footprint scanner that images targeted organs bearing radiotracers at close range.

PET/CT

Telix says new kidney cancer imaging agent alters treatment plans for 50% of patients

UCLA launches ‘first of its kind’ new standalone Department of Nuclear Medicine and Theranostics

Largest network of private cardiology groups in US to deploy GE HealthCare's cardiac PET tracer

Some PET exams may be overutilized in oncology

PSMA-PET imaging not the most cost-effective option for many prostate cancer patients